TW200817020A - Lipid-metabolism-ameliorating agent - Google Patents
Lipid-metabolism-ameliorating agent Download PDFInfo
- Publication number
- TW200817020A TW200817020A TW096130744A TW96130744A TW200817020A TW 200817020 A TW200817020 A TW 200817020A TW 096130744 A TW096130744 A TW 096130744A TW 96130744 A TW96130744 A TW 96130744A TW 200817020 A TW200817020 A TW 200817020A
- Authority
- TW
- Taiwan
- Prior art keywords
- bacillus subtilis
- culture
- serum triglyceride
- lipid metabolism
- agent
- Prior art date
Links
- 235000014469 Bacillus subtilis Nutrition 0.000 claims abstract description 31
- 244000063299 Bacillus subtilis Species 0.000 claims abstract description 30
- 210000002966 serum Anatomy 0.000 claims abstract description 23
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 21
- 230000037356 lipid metabolism Effects 0.000 claims abstract description 20
- 241000193830 Bacillus <bacterium> Species 0.000 claims abstract description 17
- 241000894006 Bacteria Species 0.000 claims abstract description 17
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 8
- 235000013305 food Nutrition 0.000 abstract description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 2
- 230000002411 adverse Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000037406 food intake Effects 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 235000010469 Glycine max Nutrition 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 244000068988 Glycine max Species 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000002689 soil Substances 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003957 anion exchange resin Substances 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 101000856500 Bacillus subtilis subsp. natto Glutathione hydrolase proenzyme Proteins 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000005206 Hibiscus Nutrition 0.000 description 1
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 description 1
- 244000284380 Hibiscus rosa sinensis Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 241000251555 Tunicata Species 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- WRRFROQOZVUOAB-KYLFFGHISA-N [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(3R)-3-hydroxy-4-[[3-[2-(3-hydroxy-3-methylpenta-1,4-dienyl)sulfanylethylamino]-3-oxopropyl]amino]-2,2-dimethyl-4-oxobutyl] hydrogen phosphate Chemical compound OC(C=CSCCNC(CCNC([C@@H](C(COP(OP(OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC=2C(N)=NC=NC1=2)O)OP(=O)(O)O)(=O)O)(=O)O)(C)C)O)=O)=O)(C=C)C WRRFROQOZVUOAB-KYLFFGHISA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- PPKJUHVNTMYXOD-PZGPJMECSA-N c49ws9n75l Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O PPKJUHVNTMYXOD-PZGPJMECSA-N 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- JQXXHWHPUNPDRT-YOPQJBRCSA-N chembl1332716 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CCN(C)CC1 JQXXHWHPUNPDRT-YOPQJBRCSA-N 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 235000008486 nectar Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 229940052337 quinupristin/dalfopristin Drugs 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- -1 semolina Substances 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
200817020 九、發明說明: 【發明所屬之技術領域】 ★本發明係關於一種脂質代謝改善劑,其係以桿菌屬之細 菌’尤其是枯草桿菌c_3102株之菌體或其培養物作為有效 、 成分,且具有降低血清三酸甘油酯值之作用。 【先前技術】 血清之三酸甘油自旨值之上升係導致高脂血症、動脈硬化 症、缺血性心臟病(心絞痛或心肌梗塞),又,糖尿病等發 • ㉟之原因,其通常成為生活習慣病之指標。又,已知飯後 中性脂肪之增加及維持係對循環系統疾病影響最大的因 素。 通常,治療高脂血症係採用藥物療法及限制脂質攝取量 之飲食療法。於藥物療法中,係使用藉由阻止膽固醇合成 途徑之自3-羥基-3-甲基戊二醯輔酶A(HMG_c〇A)合成羥戊 酸,而阻止膽固醇生物合成之HMG_c〇A還原抑制劑 (MEVALOSTATIN等)或膽汁酸吸附劑(陰離子交換樹脂)等 ⑩ 藥物。 然而,HMG-CoA還原抑制劑具有過敏症或肝功能異 • 常、橫紋肌溶解症等副作用。又,若使用膽苯烯胺等陰離 • 子交換樹脂,則陰離子交換樹脂於消化管内吸附大量含有 膽固醇之膽汁酸,阻斷其腸肝循環,而使膽固醇外排,但 其存在投與量較大難以飲用,且會引起便秘或消化管症狀 等問題。又’飲食療法由於限制飲食而伴隨有精神上之苦 痛,故而難以長期持續實施。 123765.doc 200817020 攝取,且具有 因此,業者謀求-種無副㈣且易於連續 降低血清三酸甘油酯作用的藥劑及食品。、 [專利文獻1]日本專利特公平4_24〇22 【發明内容】 [發明所欲解決之問題] 本發明之目的在於接供 、 隹於杈i、種可用於動脈硬化症等疾病之 治療及預防的脂質代謝改善劑。 [解決問題之技術手段] 本發明提供-種以屬於桿菌屬之細㈣菌體或培養物作 為有效成分之脂質代謝改善劑。x,本發明提供—種以屬 於桿菌屬之細菌的菌體或培養物作為有效成分之血清三酸 甘油醋值降低劑。屬於桿㈣之細g較好的是枯草桿菌, 更好的是枯草桿菌C-31〇2(FERM BP-1096)。 【實施方式】 桿菌屬細菌(例如,枯草桿菌(Bacillus subtUis》自古便 _ /、人類之飲艮生活息息相關,關於其機能性之資訊較多, 但尚未報告其具有降低血清三酸甘油酯之作用或改善脂質 代謝之效果。 ' 本發明之脂質代謝改善劑及血清三酸甘油酯值降低劑之 特徵在於,其含有屬於桿菌屬之細菌的菌體或其培養物, 較好的是枯草桿菌(Baeilhls subtms)之菌體或其培養物作 為有效成分。枯草桿菌之細菌學性質係記載於伯吉氏鑑別 、、田菌予手冊(Bergey’s Manual of Determinative Bacteriology)
Vohl 1(1986)等中,具體而言,例如具有以下特徵。 123765.doc 200817020 (1) 革蘭氏陽性 (2) 形成卵圓形之芽孢 (3) 桿菌 (4) 運動性:有 (5) 好氣性 (6) 觸酶:陽性 (7) 於50°C下之增殖·· + (8) 於pH5.7下之增殖:+
(9) 檸檬酸鹽之利用·· + 葡萄糠、木糠、甘露 (10)自糖類有無酸生成:阿拉伯糖 醇:+ (11) VP反應:+ (12) 澱粉之水解:+ (13) 确酸鹽之還原性:+ (14) 吲哚之生成:. (15) 白明膠之水解:+ (16) 酪蛋白之水解·· + (17) 於液體培養基中形成被囊: (18) 牛奶之凝固:_ (19) 牛奶之腺化:+ 作為本發明之脂質代謝改善劑一 w ^ ⑷叹血β二酸甘油酯值降低 劑所使用之枯草桿菌,例如 J举出·栝卓桿菌C-3102株 (生命工學業技術研究所’寄託編號ferm寄 託日期1985年12月25日)。枯草桿菌c_3102株之大豆培養 123765.doc 200817020 物對家畜具有改善腸内菌群、增加體重、感染感染、強化 卵殼、改善肉質、改善便臭等之效果,可用作添加物(曰 本專利特公平4-24022)。又,作為該株之保健效果,已知 有整腸作用、減少腸内腐敗產物等。(腸内細菌學會志, 第 18卷,第二號,93-99(2004))。 枯草桿菌C-3102具有使用下述序列1及序列2之PCR引子 進行PCR反應,可擴增大約700 bps之片斷之特徵。其他枯 草桿菌藉由該PCR引子不會引起擴增。以枯草桿菌C-3 102 之基因組作為模板擴增而成之大約700 bps之片斷之特徵 為,與澱粉酶之序列不具有同源性,該方面可明確地區別 C_3 102株與枯草桿菌之其他株。 序列 1 : 5’-GCCCCGCACATACGAAAAGACTGGCTGAAA-3’(序 列編號1) 序歹2 ·· 5,-GGATCCCACGTTGTGATTAAAAGCAGCGAT-3, (序列編號2) 進而,枯草桿菌C-3 102株具有以下性質: (1) 不具有質體DNA。 (2) 調製基因組DNA,以限制酶Notl或Sfil進行消化,再藉 由瓊脂糖電泳進行分離時之消化圖案如圖1所示。 (3) 產生B.cerous抗菌物質。 (4) 對安比西林、氯黴素、環丙沙星、紅黴素、建它黴素、 康微素、利奈嗤胺(linezolid)、奎奴普丁 /達福普;丁 (quinupristin/dalfopristin)、利福平、鏈黴素、四環素、三 曱氧苄胺嘧啶、梵谷黴素並不具有耐藥性(最低抑菌濃度 123765.doc 200817020 均為 0.03〜4 pg/ml)。
枯草桿菌可使用通常用於微生物培養之含有碳源、氣 源、無機物等之液體培養基或固體培養基作為培養基而= 行培養。作為碳源,為枯草桿菌可同化之碳源即可,例如 可舉出·葡萄糖、果糖、蔗糖、殿粉、糖蜜等;又,作為 亂源,例如可舉出:蛋白腺、酿蛋白水解物、肉汁、破酸 胺等。進而,根據需要亦可添加磷酸、鉀、鎂、鈣、:二 鐵及殼等之鹽類,維他命類,胺基酸類,卩面活性劑等。 又,除该等合成培養基以外,亦可使用大豆柏等來自天然 之物貝進行培養。作為培養條件,較好的是需氧條件,作 為培養裝置,例如較好的是利賴酵槽之通拌液體培 養衣置、棚式固體培養裝置、自動製麴培養裝置等。培養 溫度較好的是2〇〜5〇〇c、尤i ° 其好的疋30〜45c,培養時間較 、疋小時〜7日,培養初始pH值較好的是pH5〜9、 好的是pH6〜8。 、 如此而獲得之培養物包含枯草桿菌之菌體、培養基及酸 酵生成物。培養物可直接用作脂質代謝改善劑或三酸甘油 醋降低劑’亦可將培養物濃縮或對該等添加賦形劑等,製 ::燥粉末、顆粒、錠劑等製劑而使用。又,可使用自培 <物~離n亦可自培養物去㈣體而❹,亦可使 用包含囷體之形式的培養物。尤其好的態樣為:使用大豆 粕、煮大丑、煮小豆、米飯、麥飯、小麥糖、者玉且 他穀類等適合食用之來自天然之物f進行培養枯草桿菌: 不自培養物分離菌體而直接調配於食品中。 123765.doc -10 - 200817020 本發明之脂質代謝改善劍 j及血 >月二酸甘油酯值降低劑可 以液體、叙末、造粒物、旋 w寺形式投與,亦可作為食品 添加物調配於飲料食品中 f ^ 廷仃攝取。作為飲料食品,例 如可舉出:飲料、糖果片、 苗麵包、魚肉加工製品、乳 裏品等。將本發明之脂質代 、謝改善劑及血清三酸甘油酯值 降低劑添加至該等各種食σ 艮口口素材中,可作為健康飲料、健 康食品或機能性食品而提供。 如以上所述,本發明係關 u 、 開、以枯卓杯囷之菌體或其培養 物作為有效成分之具有降假 主一 、 、 > β二酉夂甘油酯之效果的脂質 代謝改善劑。作為本發明之古 有效成为的枯草桿菌為微量且 於短時間内有效,保存性乃 -文性彳良異而使其到達腸内後 可容易地進行增殖,可期锌垃鱗* μ 功待持績之降低血清三酸甘油酯作 用。 本說明書中註明引用之全邱直士丨么心 一專利及參考文獻内容均藉由 參照而編入本說明書中。又, +曱%案所具有之優先權主 張之基礎的申請案,即日本專利申七主 咛号〜甲明案2006-224672號說 明書及圖式所記載之内容亦藉由夂 稽田苓照而全部編入本說明書 中。 以下藉由實施例更加詳細說明本發明,但該等實施例並 不限制本發明之範圍。 [實施例1] 於以下實施例中,作為屬於桿菌屬之細菌的例子,係使 用枯草桿菌C-3102株(生命工學工業技術研究所,寄託編 號FERM BP-1096,寄託曰期1985年12月25曰)。 123765.doc -11 - 200817020 市口大丑粕造粒品中添加5 kg之自 121°C下進行120分鐘之鞀# ^ 尺,於 刀鐘之杈讀,接種預先培養之括 3102株的培養液,再 干囷 丹於37〇下培養40小時,藉此製造栝 朴囷C-31G2株之大豆培養物。將如此而獲得之培養物乾燥 叙碎’調配入下述表所示之其他成分,而製成工錠約_ g(匕3 3 X 1 〇個栝草桿菌芽孢)的錠劑。將錠劑之營養成 分示於表1-1,將組成示於表丨_2。
[實施例2] 阿拉伯g粉末 巴西棕櫚蠟 攝食試驗) 抑制血清三酸甘油酯上升試驗(實施人體 123765.doc -12- 200817020 試驗方法 將10名年齡25歲至40歲之健康男女(女性5名、 定為被試驗者。選定標準示於表2。再者,扔男〖生5名) 定藥劑或特定保健用食品者除外。 〃或攝取特 [表2] 將滿足以下基準,且不違背除外基準之 女 ,,c . x 々(男性5名、 性5名)定為試驗對象。 名 .锊法普愁S爲25〜而頁。 切一纟η歷星辱菜薄没石mg丽。 一^ ·····------------------------------ -------------------------------------------------------------------------〜 IU/1 ^ gItyIw1C oxaioace^c transamina^ 50 ΠΙ/?ΡΤ transaminase ^ iy/1 T-GTP(Y.glutamyl transpeptidase ^ 爾蘇縣丽—取:————: ...•••S55醫..SS運憂聽:¾¾¾ 沴杳。™....................................................................... ^ "_____J__________1二 ............................................—.........................................-.............................................. ②試驗期間,寸1¾「玉··落··百·兹T羅··€ ·······;····逼餐'·_····琢系販慕·^·· 綠J 0_________________________________ 蘭运前,司意暴^瓦昼一厂於两If 曰期°____ 被試驗者盡可能於早飯後經口攝取1日1次1錠5〇〇 mg(含 有3xl09個芽孢之枯草桿菌c_31〇2株大豆培養物的錠劑)且 持續4週。於攝食開始前、攝食1週後、2週後、3週後、4 週後、空腹時(前一日晚9時以後禁食,上午之採血時間為 固定時間)採集血液,測定血清三酸甘油酯值。試驗時間 示於表3。 123765.doc -13- 200817020 [表3] 試驗時間表(檢查項目/時間)
攝取期間(4週) 檢查項目/時間(週) 開始時 1週 2週 3週 4週 9月22曰 9月29曰 10月6日 10 月 13 10 月 20 左右 左右 左右 曰左右 日左右 [體格指數+循環系統器官檢查] 身高(初診時)、體重、休脂肪率(BI 法)、血壓、脈搏、體溫 〇 〇 〇 〇 〇 [血液生化學檢查(1)] TG、T-cho、AG比、總膽紅素量、 空腹時之血糠、GOT、GPT、AL-P、γ-GTP、殿粉酶、LDL-cho、 HDL-cho、LDH、總蛋白量、白蛋 白、UA、BUN、肌酸酐、ZTT、 Na、CL、K、Ca、離子鈣 ' P、 Mg、Fe 〇 〇 〇. 〇 〇 [血液生化學檢查(2)] PT(凝血酶原)、HP(肝促凝血酶)、 HbAlc、TT(血栓試驗)、血纖維蛋白 原、APTT(部分凝血活酶時間)、維 生素K檢查 〇 〇 〇 〇 〇 [血液常規檢查] WBC、RBC、Hb、Ht、MCV、 MCH、MCHC、血小板 〇 〇 〇 〇 〇 [尿液常規檢查] 糖、蛋白、尿瞻素原、沈積(於蛋白 為陽性之時實施) 〇 〇 〇 〇 〇 [問診:診查] 確認自知症狀、確認有害現象、確 〇 〇 〇 〇 〇 認生活日諸及指導 將上述試驗結果示於圖2。血清三酸甘油酯之變化為: 於攝取開始.時為103.6土42.82 mg/dl、攝取1週後為 69·8 土 32_00 mg/dl、攝取 2 週後為 63.0 士 24.58 mg/(H、攝取 3 週後為 77.0土35.63 mg/cU、攝取4週後為 71.8土37.26 mg/dl。 由攝取期間之平行測定單因子變異數分析之結果中可見有 意義之差異(ρ<0·01)。由多重比較(Tukey-Kraner審定)之結 • 14· 123765.doc 200817020 果可確認:攝取開始時與攝取!週後之間(p<〇 〇5)、攝取開 始時與攝取2週後之間(ρ<〇·〇5)、攝取開始時與攝取4週後 之間(ρ<0·05)存在有意義之差異。根據以上結果可明確·· 枯草桿菌C-3102株大豆培養物具有降低血清三酸甘油酯之 作用。 [產業上之可利用性] 本發明之脂質代謝改善劑可藉由為人體所攝取而降低血 清三酸甘油酯濃度,可用作動脈硬化症之預防·改善劑。 【圖式簡單說明】 圖1 A)、Β)係表示枯草桿菌c_3 1〇2株基因組dna之限制 酶Notl或Sfil消化圖。 圖2係表示攝取本發明之脂質代謝改善劑的被試驗者之 血清三酸甘油濃度之變化情況。 123765.doc 15· 200817020 序列表 <110>曰商可爾必思股份有限公司 <120脂質代謝改善劑
<130> PCP-9G06WO <140> 096130744 <141> 2007-08-20 <150> JP2006-Z24672 <151〉 2006-08-21 <160> 2 <170〉Patent In 3. 1 版 <210> 1 <211〉 30 <212> DNA 〈213>枯草桿菌
<400> 1 gccccgcaca tacgaaaaga ctggctgaaa <210> 2 <211〉 30 <212> DNA <213〉枯草桿菌 <400> 2 ggatcccacg ttgtgattaa aagcagcgat 123765.doc
Claims (1)
- 200817020 十、申請專利範圍: 1β 一種脂質代謝改善劑’其係以屬於桿菌屬之細菌培養物 作為有效成分。 2·如請求項1之脂質代謝改善劑,其中屬於桿菌屬之細菌 係枯草桿菌。 3·如請求項1或2之脂質代謝改善劑,其中屬於桿菌屬之細 菌係枯草桿菌 C-3102(FERM ΒΡ-1096)。 4 · 種血清三酸甘油酯值降低劑,其係以屬於桿菌屬之細 菌的培養物作為有效成分。 5·如請求項4之血清三酸甘油酯值降低劑,其中屬於桿菌 屬之細菌係枯草桿菌。 6.如睛求項4或5之血清三酸甘油酯值降低劑,其中屬於桿 菌屬之細菌係枯草桿菌C-3102(FERM BP-1096)。 7· 一種脂質代謝改善劑,其係以屬於桿菌屬之細菌作為有 效成分。 8. 一種脂質代謝改善劑,其係以屬於枯草桿菌之細菌作為 有效成分。 9· 一種脂質代謝改善劑’其係以枯草桿菌c-3102(FERM BP-1096)作為有效成分。 10· —種血清三酸甘油酯值降低劑,其係以屬於桿菌屬之細 囷作為有效成分。 11· 一種血清三酸甘油酯值降低劑,其係以屬於枯草桿菌之 細菌作為有效成分。 12· —種血清三酸甘油酯值降低劑,其係以枯草桿菌c_ 3102(FERM BP-1096)作為有效成分。 123765.doc
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006224672 | 2006-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200817020A true TW200817020A (en) | 2008-04-16 |
Family
ID=39106694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW096130744A TW200817020A (en) | 2006-08-21 | 2007-08-20 | Lipid-metabolism-ameliorating agent |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20100183576A1 (zh) |
| EP (1) | EP2060263A4 (zh) |
| JP (1) | JP5113057B2 (zh) |
| KR (1) | KR101454228B1 (zh) |
| CN (1) | CN101511377B (zh) |
| BR (1) | BRPI0715740A8 (zh) |
| CA (1) | CA2661373C (zh) |
| MX (1) | MX2009001782A (zh) |
| TW (1) | TW200817020A (zh) |
| WO (1) | WO2008023608A1 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011111783A1 (ja) * | 2010-03-12 | 2011-09-15 | カルピス株式会社 | 大腸におけるビフィズス菌の増加及び減少抑制剤 |
| JP6302183B2 (ja) * | 2013-07-12 | 2018-03-28 | 株式会社エンザミン研究所 | アディポサイトカイン産生バランス調整剤及び脂肪組織の炎症・酸化ストレス抑制剤並びに脂肪組織のマクロファージ浸潤抑制剤 |
| WO2016067360A1 (ja) * | 2014-10-28 | 2016-05-06 | 株式会社エンザミン研究所 | インスリン抵抗性改善剤およびインスリン抵抗性疾患予防用の健康補助食品 |
| CN118638600A (zh) * | 2022-03-24 | 2024-09-13 | 浙江省农业科学院 | 具有降血脂作用的益生菌组合物的制备设备 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63209580A (ja) * | 1987-02-25 | 1988-08-31 | Karupisu Shokuhin Kogyo Kk | バチルス・ズブチリスc−3102 |
| JPH0424022A (ja) | 1990-05-21 | 1992-01-28 | Hitachi Medical Corp | 移動形x線装置 |
| US5776756A (en) * | 1995-08-31 | 1998-07-07 | Toyo Hakko Co., Ltd. | Fermentation compositions having superoxide dismutating activity and an antihypertensive agent for treatment of constipation each having the superoxide dismutating activity |
| ATE198405T1 (de) * | 1996-02-29 | 2001-01-15 | Nutri Pharma As | Zusammensetzung, die als nahrungsmittel oder zur senkung des serumlipidspiegels geeignet ist |
| JP3489930B2 (ja) * | 1996-03-08 | 2004-01-26 | 株式会社ヤクルト本社 | がん予防食品 |
| JPH10234326A (ja) * | 1997-02-26 | 1998-09-08 | Yusuke Sugaya | 新規な大豆加工食品 |
| US6811786B1 (en) * | 1999-04-01 | 2004-11-02 | Ganeden Biotech, Inc. | Methods for reducing cholesterol using Bacillus coagulans spores, systems and compositions |
| WO1999049877A2 (en) * | 1998-04-01 | 1999-10-07 | Ganeden Biotech, Inc. | Methods for reducing cholesterol using bacillus coagulans spores, systems and compositions |
| JP2003524610A (ja) * | 1998-11-25 | 2003-08-19 | ニュートリ・ファーマ・アルメント・アクシェセルスカブ | 大豆蛋白質、食物繊維およびフィトエストロゲン化合物を含む組成物、および2型糖尿病、代謝症候群および関連する心臓血管疾患の予防および/または治療におけるその使用 |
| JP2004111573A (ja) * | 2002-09-17 | 2004-04-08 | Sony Corp | 半導体装置、及び同半導体装置の製造方法 |
| JP4309108B2 (ja) * | 2002-09-26 | 2009-08-05 | 大和薬品株式会社 | 糖尿病治療薬 |
| JP4503951B2 (ja) * | 2003-08-06 | 2010-07-14 | 株式会社琉球バイオリソース開発 | 糖尿病疾患予防・治療剤 |
| JP4001239B2 (ja) * | 2004-01-23 | 2007-10-31 | 国立大学法人京都大学 | ダイズ由来ペプチド混合物およびその利用 |
| JP2006111573A (ja) * | 2004-10-14 | 2006-04-27 | Ee H C:Kk | バチルス・サブチルス菌株の使用及びその使用に用いられる菌株を含む食品 |
| JP2006151952A (ja) | 2004-11-05 | 2006-06-15 | Oto Corporation:Kk | 高脂血症乃至高尿酸血症改善剤、及び、健康食品 |
-
2007
- 2007-08-14 MX MX2009001782A patent/MX2009001782A/es active IP Right Grant
- 2007-08-14 WO PCT/JP2007/065848 patent/WO2008023608A1/ja not_active Ceased
- 2007-08-14 EP EP07792491A patent/EP2060263A4/en not_active Withdrawn
- 2007-08-14 JP JP2008530867A patent/JP5113057B2/ja active Active
- 2007-08-14 KR KR1020097005822A patent/KR101454228B1/ko not_active Expired - Fee Related
- 2007-08-14 US US12/438,242 patent/US20100183576A1/en not_active Abandoned
- 2007-08-14 CA CA2661373A patent/CA2661373C/en not_active Expired - Fee Related
- 2007-08-14 CN CN2007800312533A patent/CN101511377B/zh not_active Expired - Fee Related
- 2007-08-14 BR BRPI0715740A patent/BRPI0715740A8/pt not_active IP Right Cessation
- 2007-08-20 TW TW096130744A patent/TW200817020A/zh unknown
-
2012
- 2012-03-12 US US13/418,032 patent/US20130017181A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN101511377B (zh) | 2012-10-03 |
| WO2008023608A1 (en) | 2008-02-28 |
| JP5113057B2 (ja) | 2013-01-09 |
| US20130017181A1 (en) | 2013-01-17 |
| CA2661373A1 (en) | 2008-02-28 |
| CN101511377A (zh) | 2009-08-19 |
| KR20090059124A (ko) | 2009-06-10 |
| US20100183576A1 (en) | 2010-07-22 |
| BRPI0715740A8 (pt) | 2017-01-24 |
| BRPI0715740A2 (pt) | 2013-07-16 |
| MX2009001782A (es) | 2009-02-25 |
| EP2060263A1 (en) | 2009-05-20 |
| JPWO2008023608A1 (ja) | 2010-01-07 |
| KR101454228B1 (ko) | 2014-10-23 |
| CA2661373C (en) | 2014-10-07 |
| EP2060263A4 (en) | 2012-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yadav et al. | Consumption of probiotic Lactobacillus fermentum MTCC: 5898-fermented milk attenuates dyslipidemia, oxidative stress, and inflammation in male rats fed on cholesterol-enriched diet | |
| CN110959676B (zh) | 一种含乳双歧杆菌的发酵乳制品及其应用 | |
| KR100899615B1 (ko) | 1,4-디히드록시-2-나프토산의 제조방법 | |
| EP2457575B1 (en) | New method for obtaining a Lactobacillus reuteri strain useful in medical and veterinary prophylaxis and treatment | |
| KR101492650B1 (ko) | 혈중 아디포넥틴 농도 증가 촉진 및/또는 감소 억제제 및 내장 지방 축적 억제제 | |
| TW200817020A (en) | Lipid-metabolism-ameliorating agent | |
| KR20180122380A (ko) | 피칼리박테리움속 세균증식제 | |
| WO2008069102A1 (ja) | 炎症性腸疾患予防治療剤 | |
| JP5229977B2 (ja) | 血中アディポネクチン濃度増加促進及び/又は減少抑制剤 | |
| JP5017271B2 (ja) | 腎機能改善剤 | |
| KR20180009630A (ko) | 2-모노아실글리세롤 절단 효소를 포함하는 간지방증 또는 비알코올성 지방간의 예방, 개선 또는 치료용 조성물 | |
| KR100523661B1 (ko) | 결장 내에서 프로피온산 및/또는 프로피오네이트를생성하기 위한 프로피온 박테리아의 용도 | |
| KR20180125895A (ko) | 락토바실러스 sp. KCCM 11826P 균주를 이용한 요독물질 축적으로 말미암아 발생하는 질환의 개선, 예방 또는 치료용 조성물 | |
| TWI909485B (zh) | 紅麴菌及其發酵產物的次級代謝物於製備減重和改善腸道菌群之組合物的用途 | |
| TWI909484B (zh) | 紅麴菌及其發酵產物的次級代謝物於製備預防或治療非酒精性脂肪肝之組合物的用途 | |
| TWI740101B (zh) | 降膽固醇之益生菌株的用途 | |
| JP2007031291A (ja) | 体重増加抑制剤及び体重増加抑制飲料 | |
| TW202547844A (zh) | 用於減重和改善腸道菌群之化合物及其組合物 | |
| WO2026023512A1 (ja) | Peptostreptococcaceae科に属する微生物の増殖抑制剤及びSlackia属微生物増殖剤 | |
| KR100691839B1 (ko) | 비피도박테리움 비피둠의 공배양을 통한 담즙산 활성효소 증가 방법 및 이를 이용한 담즙산 활성효소 증가제 | |
| KR20180090979A (ko) | 2-모노아실글리세롤 분해 효소를 포함하는 간지방증 또는 비알코올성 지방간의 예방, 개선 또는 치료용 조성물 | |
| KR20110105428A (ko) | 상황버섯 발효산물을 유효성분으로 함유하는 골손실 예방 및 치료용 조성물 |